Based on recent government reports, Medicare overpaid an estimated $529 million for anti-anemia drugs used in kidney dialysis treatement for years. As a result, kidney dialysis centers could see a 9.4% reduction in Medicare payments starting in 2014. The Wall Street Journal reports:
Kidney dialysis centers owned by DaVita Healthcare Partners Inc. (DVA) and Fresenius Medical Care AG (FMS, FME.XE) could receive 9.4% less in Medicare payments, starting in 2014, based on new rates proposed by the federal government.
News of the possible rate cuts, which came late Monday, sent shares of DaVita falling 8.4% to $111 in after-hours trading and shares of Fresenius down 3 cents to $35.47. While lower rates were expected from the Centers for Medicare and Medicaid Services, the proposed reductions were higher than some expected.
The proposed rates are open to public comment until Aug. 30, with a final ruling expected later this year.
Based on government reports, Medicare for years has overpaid for the anti-anemia drugs used in the treatment of kidney dialysis patients. One recent estimate said Medicare paid $529 million more than it should have in 2011 for the drugs made by Amgen Inc. (AMGN) and others.
Read the full story here: http://on.wsj.com/1ayEc5m
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More